Left to right: AbCellera head of BD Kevin Heyries, CEO Carl Hansen, COO Véronique Lecault, head of corporate development Murray McCutcheon

Ab­Cellera rais­es $105M in first ma­jor ven­ture round as Covid-19 an­ti­body nears clin­ic

Over its first decade of ex­is­tence, Ab­Cellera had many things: A new tech­nol­o­gy with sci-fi vibes, fund­ing from the Bill & Melin­da Gates Foun­da­tion, gov­ern­ment con­tracts, part­ner­ships with large phar­ma com­pa­nies and biotechs, a re­search fa­cil­i­ty in Van­cou­ver with dozens and then even­tu­al­ly over a hun­dred em­ploy­ees. Even, most re­cent­ly, a lead­ing ex­per­i­men­tal Covid-19 treat­ment.

They just didn’t have what al­most every biotech did: streams of ven­ture cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.